Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
OLFM4 was originally cloned from human myeloblasts and found to be selectively expressed in inflammed colonic epithelium.
Showing 10 out of 82 products:
Human Polyclonal OLFM4 Primary Antibody für ICC, IF - ABIN4341402
Dassen, Punyadeera, Delvoux, Schulkens, Marchetti, Kamps, Klomp, Dijcks, de Goeij, DHooghe, Kyama, Ederveen, Dunselman, Groothuis, Romano: Olfactomedin-4 regulation by estrogen in the human endometrium requires epidermal growth factor signaling. in The American journal of pathology 2010
Show all 2 Pubmed References
discovered that OLFM4, CD11b (zeige ITGAM Antikörper), and ITGA2 (zeige ITGA2 Antikörper) are proteins that are overexpressed in both primary colon tumors and liver metastasis. These are colon cancer biomarkers with autoantigenic properties.
MiR (zeige MLXIP Antikörper)-103 acts as an oncogene (zeige RAB1A Antikörper) miRNA to promote triple-negative breast cancer cells migration and invasion through targeting OLFM4.
OLFM4 has an important role in the regulation of intestinal inflammation and tumorigenesis, and could be a potential therapeutic target for intestinal malignant tumors. Unlike the human colonic epithelium, the mouse colonic epithelium does not express OLFM4, but nevertheless, systemic OLFM4 deletion promotes colon tumorigenesis and that loss from mucosal neutrophils may have a role to play.
Olfactomedin-4 identifies a subpopulation of neutrophils in patients with septic shock, and those with a high percentage of olfactomedin-4+ neutrophils are at higher risk for greater organ failure burden and death. Olfactomedin-4 might serve as a marker of a pathogenic neutrophil subset in patients with septic shock
OLFM4 is proved to as a functional target for miR (zeige MLXIP Antikörper)-590.
Olfactomedin 4 is a novel tumor marker for triple-negative breast cancer for predicting and prognosis.
OLFM4 is downregulated by miR (zeige MLXIP Antikörper)-486-5p, which contributes to ovarian cancer tumorigenesis. Conversely, estrogen receptor (zeige ESR1 Antikörper) signaling downregulates miR (zeige MLXIP Antikörper)-486-5p and upregulates OLFM4 expression, slowing the development and progression of ovarian cancer.
Data show that olfactomedin 4 (OLFM4) is highly expressed in proliferating benign epithelial cells and in some carcinoma cells.
olfactomedin 4 appears to play a critical role in regulating progression of prostate cancer, and has potential as a new biomarker for prostate cancer.
Study demonstrates that epigenetic silencing of OLFM4 enhances gastric cancer cell invasion via activation of FAK (zeige PTK2 Antikörper) signaling.
OLFM4 may function as a tumor suppressor and an anti-metastatic gene during tumor progression
Olfm4 deletion can successfully enhance immune defense against S. aureus, but not A. fumigatus, in chronic granulomatous disease mice.
OLFM4 exerts considerable influence on the host defense against H. pylori infection acting through NOD1 (zeige NOD1 Antikörper) and NOD2 (zeige NOD2 Antikörper) mediated NF-kappaB (zeige NFKB1 Antikörper) activation and subsequent cytokines and chemokines production, which in turn inhibit host immune response.
This gene was originally cloned from human myeloblasts and found to be selectively expressed in inflammed colonic epithelium. This gene encodes a member of the olfactomedin family. The encoded protein is an antiapoptotic factor that promotes tumor growth and is an extracellular matrix glycoprotein that facilitates cell adhesion.
, G-CSF-stimulated clone 1 protein
, antiapoptotic protein GW112
, PU.1 difference product 4